Ian is a highly experienced pharmaceutical professional and leader delivering the highest quality compounding and clinical homecare services across the UK.
Since April 2022, Ian Muir has served as Chief Executive Officer of Pharmaxo Group – steering the organisation through a period of stabilisation, strategic realignment and rapid growth.
Under his leadership, the Group re-branded, and was acquired by Icon Group in 2024, enabling new capability to deliver high-quality aseptic compounding and clinical homecare services across the UK.
Ian is responsible for shaping Pharmaxo’s growth strategy, strengthening operational performance across its manufacturing and home-infusion network, and embedding a culture of quality and patient-centred care.
A Pharmacist by training, Ian holds a PhD in pharmaceutical science and brings more than three decades of international pharmaceutical and life science experience. He has held senior commercial, R&D and manufacturing roles with Catalent globally, in addition to Aesica, Famar and Porton Biopharm as CEO. He was a member of the UK Vaccine Task Force for vaccine manufacture as well as advising financial and industry investors on M&A in the sector. This breadth of leadership gives him a deep understanding of the end-to-end pharmaceutical value chain.